TENAYA THERAPEUTICS INC. - COMMON STOCK

Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

17 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

16 Dec 2024 15:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

25 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

19 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

06 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

17 Oct 2024 15:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming Investment Conferences

03 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

08 Aug 2024 15:05:01 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Research Leadership Updates

27 Jun 2024 16:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

18 Jun 2024 15:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

14 May 2024 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

02 May 2024 16:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

18 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

18 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

27 Feb 2024 15:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

26 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Pricing of Underwritten Offering

08 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

21 Nov 2023 15:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

08 Nov 2023 15:05:00 By Nasdaq GlobeNewswire